View in EDS HTML Full Text PDF Full Text

Mechanistic safety assessment via multi-omic characterisation of systemic pathway perturbations following in vivo MAT2A inhibition.

Saved in:
Bibliographic Details
Title: Mechanistic safety assessment via multi-omic characterisation of systemic pathway perturbations following in vivo MAT2A inhibition.
Authors: Fogal V; Oncology Safety, Safety Sciences, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK.; Cancer Metabolism & Systems Toxicology Group, Division of Cancer, Department of Surgery and Cancer, Imperial College London, London, UK., Michopoulos F; Bioscience, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK., Jarnuczak AF; Data Sciences & Quantitative Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK., Hamza GM; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, R&D Boston, Waltham, USA., Harlfinger S; DMPK, Oncology R&D, AstraZeneca, Cambridge, UK., Davey P; Chemistry, Oncology R&D AstraZeneca, Cambridge, UK., Hulme H; Imaging and Data Analytics, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK., Atkinson SJ; Chemistry, Oncology R&D AstraZeneca, Cambridge, UK., Gabrowski P; Biological Insights Knowledge Graph, R&D IT, AstraZeneca, Barcelona, Spain., Cheung T; Oncology R&D, AstraZeneca, R&D Boston, Waltham, USA., Grondine M; Oncology R&D, AstraZeneca, R&D Boston, Waltham, USA., Hoover C; Oncology Safety Pathology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, R&D Boston, Waltham, USA., Rose J; Animal Science & Technologies, R&D, AstraZeneca, Cambridge, UK., Bray C; Cancer Metabolism & Systems Toxicology Group, Division of Cancer, Department of Surgery and Cancer, Imperial College London, London, UK., Foster AJ; Regulatory Toxicology and Safety Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK., Askin S; Advanced Drug Delivery, Pharmaceutical Sci, R&D, AstraZeneca, Cambridge, UK., Majumder MM; Safety Sciences, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Fitzpatrick P; Safety Sciences, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Miele E; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, R&D Boston, Waltham, USA., Macdonald R; Animal Science & Technologies, R&D, AstraZeneca, Cambridge, UK., Keun HC; Cancer Metabolism & Systems Toxicology Group, Division of Cancer, Department of Surgery and Cancer, Imperial College London, London, UK., Coen M; Oncology Safety, Safety Sciences, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK. muireann.coen@astrazeneca.com.
Source: Archives of toxicology [Arch Toxicol] 2024 Aug; Vol. 98 (8), pp. 2589-2603. Date of Electronic Publication: 2024 May 17.
Publication Type: Journal Article
Journal Info: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 0417615 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0738 (Electronic) Linking ISSN: 03405761 NLM ISO Abbreviation: Arch Toxicol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38755480
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Mechanistic safety assessment via multi-omic characterisation of systemic pathway perturbations following in vivo MAT2A inhibition.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Fogal+V%22">Fogal V</searchLink>; Oncology Safety, Safety Sciences, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK.; Cancer Metabolism & Systems Toxicology Group, Division of Cancer, Department of Surgery and Cancer, Imperial College London, London, UK.<br /><searchLink fieldCode="AU" term="%22Michopoulos+F%22">Michopoulos F</searchLink>; Bioscience, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Jarnuczak+AF%22">Jarnuczak AF</searchLink>; Data Sciences & Quantitative Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Hamza+GM%22">Hamza GM</searchLink>; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, R&D Boston, Waltham, USA.<br /><searchLink fieldCode="AU" term="%22Harlfinger+S%22">Harlfinger S</searchLink>; DMPK, Oncology R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Davey+P%22">Davey P</searchLink>; Chemistry, Oncology R&D AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Hulme+H%22">Hulme H</searchLink>; Imaging and Data Analytics, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Atkinson+SJ%22">Atkinson SJ</searchLink>; Chemistry, Oncology R&D AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Gabrowski+P%22">Gabrowski P</searchLink>; Biological Insights Knowledge Graph, R&D IT, AstraZeneca, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Cheung+T%22">Cheung T</searchLink>; Oncology R&D, AstraZeneca, R&D Boston, Waltham, USA.<br /><searchLink fieldCode="AU" term="%22Grondine+M%22">Grondine M</searchLink>; Oncology R&D, AstraZeneca, R&D Boston, Waltham, USA.<br /><searchLink fieldCode="AU" term="%22Hoover+C%22">Hoover C</searchLink>; Oncology Safety Pathology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, R&D Boston, Waltham, USA.<br /><searchLink fieldCode="AU" term="%22Rose+J%22">Rose J</searchLink>; Animal Science & Technologies, R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Bray+C%22">Bray C</searchLink>; Cancer Metabolism & Systems Toxicology Group, Division of Cancer, Department of Surgery and Cancer, Imperial College London, London, UK.<br /><searchLink fieldCode="AU" term="%22Foster+AJ%22">Foster AJ</searchLink>; Regulatory Toxicology and Safety Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Askin+S%22">Askin S</searchLink>; Advanced Drug Delivery, Pharmaceutical Sci, R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Majumder+MM%22">Majumder MM</searchLink>; Safety Sciences, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Fitzpatrick+P%22">Fitzpatrick P</searchLink>; Safety Sciences, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Miele+E%22">Miele E</searchLink>; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, R&D Boston, Waltham, USA.<br /><searchLink fieldCode="AU" term="%22Macdonald+R%22">Macdonald R</searchLink>; Animal Science & Technologies, R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Keun+HC%22">Keun HC</searchLink>; Cancer Metabolism & Systems Toxicology Group, Division of Cancer, Department of Surgery and Cancer, Imperial College London, London, UK.<br /><searchLink fieldCode="AU" term="%22Coen+M%22">Coen M</searchLink>; Oncology Safety, Safety Sciences, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK. muireann.coen@astrazeneca.com.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220417615%22">Archives of toxicology</searchLink> [Arch Toxicol] 2024 Aug; Vol. 98 (8), pp. 2589-2603. <i>Date of Electronic Publication: </i>2024 May 17.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer-Verlag%22">Springer-Verlag </searchLink><i>Country of Publication: </i>Germany <i>NLM ID: </i>0417615 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1432-0738 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203405761%22">03405761 </searchLink><i>NLM ISO Abbreviation: </i>Arch Toxicol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38755480
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s00204-024-03771-w
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2589
    Titles:
      – TitleFull: Mechanistic safety assessment via multi-omic characterisation of systemic pathway perturbations following in vivo MAT2A inhibition.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Fogal V
      – PersonEntity:
          Name:
            NameFull: Michopoulos F
      – PersonEntity:
          Name:
            NameFull: Jarnuczak AF
      – PersonEntity:
          Name:
            NameFull: Hamza GM
      – PersonEntity:
          Name:
            NameFull: Harlfinger S
      – PersonEntity:
          Name:
            NameFull: Davey P
      – PersonEntity:
          Name:
            NameFull: Hulme H
      – PersonEntity:
          Name:
            NameFull: Atkinson SJ
      – PersonEntity:
          Name:
            NameFull: Gabrowski P
      – PersonEntity:
          Name:
            NameFull: Cheung T
      – PersonEntity:
          Name:
            NameFull: Grondine M
      – PersonEntity:
          Name:
            NameFull: Hoover C
      – PersonEntity:
          Name:
            NameFull: Rose J
      – PersonEntity:
          Name:
            NameFull: Bray C
      – PersonEntity:
          Name:
            NameFull: Foster AJ
      – PersonEntity:
          Name:
            NameFull: Askin S
      – PersonEntity:
          Name:
            NameFull: Majumder MM
      – PersonEntity:
          Name:
            NameFull: Fitzpatrick P
      – PersonEntity:
          Name:
            NameFull: Miele E
      – PersonEntity:
          Name:
            NameFull: Macdonald R
      – PersonEntity:
          Name:
            NameFull: Keun HC
      – PersonEntity:
          Name:
            NameFull: Coen M
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Text: 2024 Aug
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1432-0738
          Numbering:
            – Type: volume
              Value: 98
            – Type: issue
              Value: 8
          Titles:
            – TitleFull: Archives of toxicology
              Type: main
ResultId 1